
Moderna shares dropped about 2% to $33.60 early Monday after the biotech forecasted around $1.9 billion in revenue for 2025 and lowered its GAAP operating-expense forecast for that year—the U.S. accounting standard. The stock swung between $35.77 and $33.33 in a volatile session.
Today’s highest-ranked model selections.
The catalysts most likely to move markets.
A surprise around the 0.10 forecast could shift the morning growth narrative and influence Treasury yields and the dollar before the opening bell.
The day’s largest scheduled equity report can move PDD and the broader China-internet / e-commerce complex through revenue growth, margins and Temu commentary.
Deliveries, margin progression and spending on AI-enabled mobility can affect U.S.-traded Chinese EV names and related technology suppliers.